# Immunomodulatory Properties of Ketamine in Sepsis

> **NCT01089361** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 19 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Normal Saline placebo

## Key facts

- **NCT ID:** NCT01089361
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-06
- **Final completion:** 2011-06
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01089361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01089361, "Immunomodulatory Properties of Ketamine in Sepsis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01089361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*